DUBLIN--(BUSINESS WIRE)--The "Leukapheresis Market by Product (Devices, Filters, Columns, Disposables), Leukopak (Mobilized, Non-Mobilized), Indication (ALL, NHL, Multiple Myeloma), Application (Research, Therapeutic), End User (Hospitals, Pharma, Biotech) - Global Forecast to 2026" report has been added to ResearchAndMarkets.com's offering.
The global leukapheresis products market is projected to reach USD 91 million by 2026 from USD 61 million in 2021, at a CAGR of 8.4% during the forecast period.
The leukapheresis disposables segment holds the highest market share, by product, in the leukapheresis products market, in the forecast period.
On the basis of product, the leukapheresis market is broadly segmented into leukapheresis disposables and leukapheresis devices. Leukapheresis devices are further segmented into centrifugal devices and membrane separators. The large share of the leukapheresis disposables segment can be attributed to the recurrent use of disposables during leukapheresis procedures, increasing adoption of leukapheresis products for the collection of leukopaks and isolated PBMCs from leukopaks for research applications, and the increasing adoption of therapeutic leukapheresis procedures.
The centrifugal devices segment to grow at the highest CAGR in the leukapheresis devices market, in the forecast period.
Based on type, the leukapheresis devices market is broadly segmented into centrifugal devices and membrane separators. Centrifugal devices segment is expected to grow at the highest CAGR during the forecast period. The high growth of this segment can be attributed to the increasing installation of centrifugal apheresis devices in hospitals for therapeutic apheresis.
Increasing adoption of leukapheresis products for the development of cell-based immunotherapies to promote the growth of this segment in the forecast period.
Based on application, the leukapheresis products market is segmented into research and therapeutic applications. The research applications segment accounted for the largest share of the leukapheresis products market during the forecast period. The large share of this segment is attributed to the increasing adoption of leukapheresis products for the development of cell-based immunotherapies and leukapheresis-derived primary cells in drug development.
In the leukapheresis products market by end-user segment, blood component providers & blood centers segment holds the highest market share
On the basis of end-user, the leukapheresis products market is segmented into blood component providers & blood centers, academic and research institutes, pharmaceutical & biotechnology companies, hospitals & transfusion centers. Blood component providers & blood centers hold the largest share in this market. The large share of this segment can be attributed to the growing demand for leukopaks for the development of CAR T-cell therapies, and the increasing demand for blood components in clinical conditions such as cancer.
In the leukopaks market by type, the diseased leukopaks segment is projected to grow at the highest rate in the forecast period
Based on type, the leukopaks market is segmented into mobilized leukopaks, non-mobilized leukopaks, diseased leukopaks, and isolated PBMCs. In this segment, the diseased leukopaks segment is projected to register the highest growth during the forecast period. The increasing demand for diseased-state leukopaks for cell interaction studies, drug toxicity studies, preclinical development of cell-based therapeutics, immunotherapy, immune-oncology studies, and regenerative medicine is driving the growth of this segment.
Acute Lymphocytic Leukemia holds the largest share in the leukopaks market, by indication, in the forecast period
Based on indication, the leukopaks market is segmented into acute lymphocytic leukemia, chronic lymphocytic leukemia, non-Hodgkin's lymphoma, multiple myeloma, hepatocellular carcinoma, pancreatic cancer, and other indications (colorectal cancer, neuroblastoma, breast cancer, and acute myeloid leukemia). The acute lymphocytic leukemia segment accounts for the largest share of the leukopaks market, by indication. The large share of this segment can be attributed to the increasing focus of pharmaceutical companies on the development of leukopak-based cell therapies for the treatment of acute lymphocytic leukemia (ALL) and a high number of CAR T-cell therapy clinical trials for ALL.
Mobilized Lymphocytic Leukemia holds the largest share in the leukopaks market, by indication, in the forecast period
Based on indication, the leukopaks market is segmented into mobilized leukopaks, non-mobilized leukopaks, diseased leukopaks, and isolated PBMCs. In this segment, the diseased leukopaks segment is projected to register the highest growth during the forecast period. The increasing demand for diseased-state leukopaks for cell interaction studies, drug toxicity studies, preclinical development of cell-based therapeutics, immunotherapy, immune-oncology studies, and regenerative medicine is driving the growth of this segment.
Market Dynamics
Drivers
- Increasing Incidence and Prevalence of Leukemia
- Increasing Number of Blood Donations
- Demand for Leukopaks in Clinical Research
Restraints
- High Cost of Therapeutic Leukapheresis and Leukopaks
- Stringent Donor Recruitment Criteria
- Dearth of Skilled Professionals and Low Adoption of Therapeutic Leukapheresis
- Complications Associated with Therapeutic Leukapheresis
- Long Procedural Time for Leukapheresis
- High Cost of Cellular Immunotherapies & Lack of Favorable Reimbursement
Opportunities
- Leukapheresis for Pediatric Patients
- Emerging Economies and Increasing Investments from Academic Institutes, Pharma-Biotech Companies, and Leading Players
Challenges
- Blood Transfusion Safety in Developing Countries
Companies Mentioned
- Allcells, LLC
- Asahi Kasei Corporation
- Beijing Zksk Technology Co. Ltd.
- Bioivt
- Caltag Medsystems Limited
- Charles River Laboratories International, Inc.
- Discovery Life Sciences
- Fresenius Se & Co. Kgaa
- Guangzhou Daji Medical Science and Technology Co. Ltd.
- Haemonetics Corporation
- Intelligent Tissue Group
- Lonza Group Ag
- Macopharma Sa
- Medica Spa.
- Miltenyi Biotec
- Precision for Medicine, Inc.
- Puriblood Medical Co. Ltd.
- Stemexpress, LLC
- Terumo BCT
- Zenbio, Inc.
For more information about this report visit https://www.researchandmarkets.com/r/l086dn
